Targeting FGFR signaling in cancer

M Touat, E Ileana, S Postel-Vinay, F André… - Clinical cancer …, 2015 - AACR
The fibroblast growth factor signaling pathway (FGFR signaling) is an evolutionary
conserved signaling cascade that regulates several basic biologic processes, including …

FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice

A Kommalapati, SH Tella, M Borad, M Javle, A Mahipal - Cancers, 2021 - mdpi.com
Simple Summary FGFR inhibitors evolved as therapeutic options in cholangiocarcinoma
and urothelial malignancies. Given the implications of FGFR pathway in various …

[HTML][HTML] Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application

YK Chae, K Ranganath, PS Hammerman, C Vaklavas… - Oncotarget, 2017 - ncbi.nlm.nih.gov
The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) is a tyrosine kinase
signaling pathway that has a fundamental role in many biologic processes including …

Facts and new hopes on selective FGFR inhibitors in solid tumors

F Facchinetti, A Hollebecque, R Bahleda, Y Loriot… - Clinical Cancer …, 2020 - AACR
Precision oncology relies on the identification of molecular alterations, responsible for tumor
initiation and growth, which are suitable targets of specific inhibitors. The development of …

[HTML][HTML] A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma …

E Van Cutsem, YJ Bang, W Mansoor, RD Petty… - Annals of …, 2017 - Elsevier
ABSTRACT Background Approximately 5%–10% of gastric cancers have a fibroblast growth
factor receptor-2 (FGFR2) gene amplification. AZD4547 is a selective FGFR-1, 2, 3 tyrosine …

Prevention and treatment of FGFR inhibitor-associated toxicities

A Mahipal, SH Tella, A Kommalapati, J Yu… - Critical Reviews in …, 2020 - Elsevier
Fibroblast growth factor receptor (FGFR) inhibitors have shown promising results in terms of
objective response rates in phase I/II trials in various malignancies that harbor FGFR genetic …

Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study

H Saka, C Kitagawa, Y Kogure, Y Takahashi… - Investigational new …, 2017 - Springer
Background AZD4547 is a potent, oral, highly selective fibroblast growth factor receptor
(FGFR) inhibitor in clinical development for treating tumours with a range of FGFR …

Complexity of FGFR signalling in metastatic urothelial cancer

A Rodriguez-Vida, M Saggese, S Hughes… - Journal of Hematology & …, 2015 - Springer
Background Urothelial cancers (UC) are the fourth most common tumours worldwide after
prostate (or breast), lung and colorectal cancer. Despite recent improvements in their …

[HTML][HTML] Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?

C Hierro, M Alsina, M Sánchez, V Serra, J Rodon… - Annals of …, 2017 - Elsevier
Gastric cancer is the third leading cause of death from cancer worldwide. Systemic
chemotherapy remains the mainstay therapeutic option for this poor prognosis cancer …

ASP5878, a novel inhibitor of FGFR1, 2, 3, and 4, inhibits the growth of FGF19-expressing hepatocellular carcinoma

T Futami, H Okada, R Kihara, T Kawase… - Molecular Cancer …, 2017 - AACR
Hepatocellular carcinoma is an aggressive cancer with poor prognosis. Fibroblast growth
factor 19, a member of the fibroblast growth factor family, is a ligand for fibroblast growth …